Russell Investments Group Ltd. Has $534,000 Stock Holdings in Harrow Health, Inc. (NASDAQ:HROW)

Russell Investments Group Ltd. lessened its position in shares of Harrow Health, Inc. (NASDAQ:HROW) by 53.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,223 shares of the company’s stock after selling 29,475 shares during the quarter. Russell Investments Group Ltd. owned about 0.08% of Harrow Health worth $534,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in HROW. Envestnet Asset Management Inc. acquired a new position in shares of Harrow Health during the first quarter valued at $70,000. BlackRock Inc. lifted its stake in Harrow Health by 1.2% in the first quarter. BlackRock Inc. now owns 436,528 shares of the company’s stock valued at $2,978,000 after buying an additional 5,261 shares during the period. Wasatch Advisors Inc. lifted its stake in Harrow Health by 11.2% in the first quarter. Wasatch Advisors Inc. now owns 740,104 shares of the company’s stock valued at $5,048,000 after buying an additional 74,800 shares during the period. Prelude Capital Management LLC lifted its stake in Harrow Health by 34.4% in the first quarter. Prelude Capital Management LLC now owns 94,911 shares of the company’s stock valued at $647,000 after buying an additional 24,293 shares during the period. Finally, State Street Corp lifted its stake in Harrow Health by 5.5% in the first quarter. State Street Corp now owns 86,813 shares of the company’s stock valued at $592,000 after buying an additional 4,521 shares during the period. Institutional investors and hedge funds own 75.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on HROW shares. B. Riley increased their target price on Harrow Health from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, July 20th. LADENBURG THALM/SH SH increased their target price on Harrow Health from $33.70 to $34.40 in a research note on Thursday, August 10th.

Insider Transactions at Harrow Health

In other Harrow Health news, Director Martin A. Makary purchased 20,000 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were bought at an average price of $16.92 per share, with a total value of $338,400.00. Following the completion of the transaction, the director now directly owns 45,000 shares in the company, valued at approximately $761,400. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Harrow Health news, CEO Mark L. Baum bought 5,800 shares of Harrow Health stock in a transaction dated Monday, August 14th. The stock was bought at an average cost of $17.05 per share, for a total transaction of $98,890.00. Following the purchase, the chief executive officer now owns 2,015,461 shares of the company’s stock, valued at approximately $34,363,610.05. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Martin A. Makary bought 20,000 shares of Harrow Health stock in a transaction dated Monday, August 14th. The shares were acquired at an average price of $16.92 per share, with a total value of $338,400.00. Following the completion of the purchase, the director now directly owns 45,000 shares in the company, valued at approximately $761,400. The disclosure for this purchase can be found here. 13.60% of the stock is currently owned by insiders.

Harrow Health Trading Up 2.1 %

NASDAQ HROW opened at $15.49 on Friday. The firm has a market cap of $544.01 million, a P/E ratio of -27.66 and a beta of 0.19. The company has a debt-to-equity ratio of 7.70, a current ratio of 2.62 and a quick ratio of 2.25. The stock’s 50-day moving average is $18.54 and its 200-day moving average is $20.07. Harrow Health, Inc. has a one year low of $7.51 and a one year high of $28.25.

Harrow Health (NASDAQ:HROW) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). The business had revenue of $33.47 million for the quarter, compared to analyst estimates of $31.04 million. Harrow Health had a negative return on equity of 5.38% and a negative net margin of 15.85%. The company’s revenue for the quarter was up 43.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.01 EPS. Sell-side analysts anticipate that Harrow Health, Inc. will post -0.14 earnings per share for the current fiscal year.

Harrow Health Company Profile

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.